DE69905488D1 - Prostaglandin-konjugate zur behandlung von knochenkrankheiten - Google Patents

Prostaglandin-konjugate zur behandlung von knochenkrankheiten

Info

Publication number
DE69905488D1
DE69905488D1 DE69905488T DE69905488T DE69905488D1 DE 69905488 D1 DE69905488 D1 DE 69905488D1 DE 69905488 T DE69905488 T DE 69905488T DE 69905488 T DE69905488 T DE 69905488T DE 69905488 D1 DE69905488 D1 DE 69905488D1
Authority
DE
Germany
Prior art keywords
conjugates
prostaglandin
bone diseases
treating bone
prostaglandin conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69905488T
Other languages
English (en)
Other versions
DE69905488T2 (de
Inventor
Laurent Gil
Yongxin Han
Rejean Ruel
N Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of DE69905488D1 publication Critical patent/DE69905488D1/de
Application granted granted Critical
Publication of DE69905488T2 publication Critical patent/DE69905488T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3869—Polyphosphonic acids containing carboxylic acid or carboxylic acid derivative substituents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3865—Polyphosphonic acids containing sulfur substituents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69905488T 1998-11-20 1999-11-18 Prostaglandin-konjugate zur behandlung von knochenkrankheiten Expired - Fee Related DE69905488T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930798P 1998-11-20 1998-11-20
PCT/CA1999/001111 WO2000031084A1 (en) 1998-11-20 1999-11-18 Prostaglandin conjugates for treating or preventing bone disease

Publications (2)

Publication Number Publication Date
DE69905488D1 true DE69905488D1 (de) 2003-03-27
DE69905488T2 DE69905488T2 (de) 2003-12-24

Family

ID=22326974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905488T Expired - Fee Related DE69905488T2 (de) 1998-11-20 1999-11-18 Prostaglandin-konjugate zur behandlung von knochenkrankheiten

Country Status (9)

Country Link
US (1) US6121253A (de)
EP (1) EP1131327B1 (de)
JP (1) JP2002530411A (de)
AT (1) ATE232874T1 (de)
AU (1) AU762396B2 (de)
CA (1) CA2351679A1 (de)
DE (1) DE69905488T2 (de)
ES (1) ES2191475T3 (de)
WO (1) WO2000031084A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
TWI290144B (en) 1999-01-20 2007-11-21 Takara Bio Inc 4-substituded-3,6-anhydro-galactose derivatives and their pharmaceutical use
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
IL147771A0 (en) * 1999-08-04 2002-08-14 Procter & Gamble Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US20010041743A1 (en) * 2000-01-12 2001-11-15 Steven Offenbacher Use of cyclopentenone derivatives for bone and periodontal regeneration
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EP1383510B1 (de) * 2001-04-10 2012-10-17 MBC Pharma, Inc. Bisphosphonat-konjugate und verfahren zu ihrer herstellung und verwendung
AU2003231255A1 (en) * 2002-05-02 2003-12-31 Osteoscreen, Inc. Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate)
EP1723132A1 (de) 2004-02-12 2006-11-22 Asterand Uk Limited Agonisten des ep2-rezeptors
EP1951701A2 (de) 2005-08-09 2008-08-06 Asterand Uk Limited Agonisten des ep2-rezeptors
EP1988907A4 (de) * 2006-02-06 2010-04-14 Cypress Bioscience Inc Zusammensetzungen mit einem bisphosphonat und einem antifolat
EP2155769B1 (de) * 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Schutz gegen gewebedegeneration
US20090124695A1 (en) 2007-11-14 2009-05-14 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
CA2843885C (en) 2011-08-01 2020-03-10 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975404A (en) * 1971-05-04 1976-08-17 The Upjohn Company Bicyclic lactone intermediates
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US4018892A (en) * 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
EP0381296B1 (de) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Ausrüstung für die Verwendung bei der Behandlung von Osteoporose
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
DE3519361A1 (de) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US5071840A (en) * 1986-12-19 1991-12-10 Norwich Eaton Pharmaceuticals, Inc. Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism
EP0341961A3 (de) * 1988-05-09 1990-06-20 Merck & Co. Inc. Polymalonsäuren als Knochenaffinitätsagent
JPH0778024B2 (ja) * 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
JPH0759505B2 (ja) * 1988-11-17 1995-06-28 帝人株式会社 シクロペンテノン類を活性成分とする骨形成促進剤
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
EP0496520A1 (de) * 1991-01-22 1992-07-29 Merck & Co. Inc. Knochenaktive Verbindungen
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
NZ253524A (en) * 1992-05-29 1997-01-29 Procter & Gamble Pharma Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism)
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis

Also Published As

Publication number Publication date
US6121253A (en) 2000-09-19
WO2000031084A1 (en) 2000-06-02
EP1131327B1 (de) 2003-02-19
AU762396B2 (en) 2003-06-26
DE69905488T2 (de) 2003-12-24
ATE232874T1 (de) 2003-03-15
JP2002530411A (ja) 2002-09-17
CA2351679A1 (en) 2000-06-02
AU1255600A (en) 2000-06-13
EP1131327A1 (de) 2001-09-12
ES2191475T3 (es) 2003-09-01

Similar Documents

Publication Publication Date Title
DE69905488T2 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
SE9901272D0 (sv) New improved formulation
BR0016058A (pt) Compostos de fosfonato
DE69331326D1 (de) Prostaglandin-analoga zur behandlung von osteoporose
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
DE60113537D1 (de) Methode zur verabreichung von biphosphonaten
DE69905476T2 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE293450T1 (de) Verwendung von biphosphonsäuren zur behandlung von angiogenese
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
TR199902703T2 (xx) Proteaz inhibit�rleri.
DE122007000063I1 (de) Alendronate zur Behandlung von Osteoporose
DE69730796D1 (de) Naphthylverbindungen, Zusammensetzungen und Verfahren
ATE284221T1 (de) Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
ATE263566T1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
DE69921346D1 (de) Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption
ATE245637T1 (de) Benzothiophenverbindungen, zubereitungen und verfahren
DE69934113D1 (de) Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE272651T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
FR2783518B1 (fr) Inhibiteurs de lta4 hydrolase
ATE224735T1 (de) Mittel zur spezifischen hemmung osteoklastärer knochenresorption
DE59509229D1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien
DE69711528D1 (de) Naphthofluorenverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee